Circulating BDNF in pediatric neurodevelopmental disorders: a meta-analysis of case-control differences and cognitive severity.

What was studied

This study looked at a blood marker called BDNF. Some think it may show problems with thinking and learning. The team looked at children and teens with cerebral palsy, intellectual disability, or Down syndrome. They pulled together results from earlier studies in a meta-analysis. Searches found 340 records, and 7 studies were kept. These held at least 547 people.

What they found

Some of the studies could be combined, with 322 people in total. The pooled data showed no clear difference in BDNF. This compared affected children with children without these conditions. Results varied a great deal from study to study. Splitting studies by type of condition did not make them more alike. An extra check with more Down syndrome data gave the same answer.

What it means for patients

The authors say BDNF is not a reliable marker in these children for now. It did not clearly show who had problems with thinking. It also did not clearly track how severe these problems were. Results even pointed in different ways within the same condition. The authors think this comes from how the studies were done. They do not think it shows a true, repeatable signal in the body.

Why it is not certain yet

Only some of the 7 studies could be pooled. The studies differed a lot in their methods. They used different lab tests to measure BDNF. Control groups were not always the same age as the affected children. Some data were missing or only shown in figures. The authors call for new studies with same-age controls and standard lab tests.

Source

Circulating BDNF in pediatric neurodevelopmental disorders: a meta-analysis of case-control differences and cognitive severity.

We restate facts from the source record in our own words. The original wording belongs to its publisher.